Hesse R J, Swan J L
Department of Ophthalmology, Ochsner Clinic, New Orleans, Louisiana.
Ophthalmic Surg. 1988 Aug;19(8):562-4.
Since the approval of timolol for the treatment of open-angle glaucoma, beta-adrenergic blocking drugs have replaced epinephrine, a pure alpha and beta agonist, as the treatment of choice for glaucoma in aphakic patients. To date, there have been no reports of cystoid macular edema secondary to timolol, a non-selective beta-adrenergic blocker that apparently has little intrinsic sympathomimetic activity. Betaxolol is a new beta-adrenergic receptor blocker that preferentially blocks beta 1 receptors. We report a case of angiographically proven cystoid macular edema secondary to betaxolol therapy that resolved after discontinuation and recurred after a monocular therapeutic trial.
自从噻吗洛尔被批准用于治疗开角型青光眼以来，β-肾上腺素能阻滞剂已取代肾上腺素（一种纯α和β激动剂），成为无晶状体患者青光眼的首选治疗药物。迄今为止，尚无关于噻吗洛尔（一种非选择性β-肾上腺素能阻滞剂，显然几乎没有内在拟交感活性）继发黄斑囊样水肿的报道。倍他洛尔是一种新型β-肾上腺素能受体阻滞剂，优先阻断β1受体。我们报告了一例经血管造影证实的倍他洛尔治疗继发黄斑囊样水肿的病例，该病例在停药后消退，在单眼治疗试验后复发。
